RenovoRx, Inc. (RNXT) research
RenovoRx, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.58
- As of
RenovoRx, Inc. (RNXT): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-20.
As of . Source: SEC EDGAR filings for RNXT. Method and limitations.
Share the RNXT intelligence card
See the full RNXT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RNXT on one page. Preview it with sample data, then open it live with a free account.
Preview the RNXT dossierActive signals for RNXT
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +150% to RNXT (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 32.4%, EPS $-0.05 vs $-0.074 estimate
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 89% of RNXT (2026Q1)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 7.7% - EPS $-0.08 vs $-0.0867 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 10.3% - EPS $-0.09 vs $-0.0816 estimate
FREE, NO ACCOUNT
Every signal on RNXT, as it fires
New filings, 13F moves and cross asset signals on RNXT land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RNXT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 75989R107 · 2026Q2 | $131K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 75989R107 · 2026Q2 | $11K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RNXT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RNXT against its peers
RNXT's operating margin of -1114.0% ranks in the 17th percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | RNXT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.1M USD | 12.6M USD | 38 | 11 |
| Gross margin | 70.9% | n/a | n/a | 3 |
| Operating margin | -1114.0% | -55.1% | 17 | 8 |
| Net margin | -994.5% | -31.7% | 17 | 8 |
| Return on equity | -206.0% | -74.2% | 25 | 17 |
Peers (21): ALDX, CING, GOSS, SPRO, CSBR, MAIA, KLRS, FBIO, PMVP, HRTX, TENX, XBIT, GUTS, ATHE, OSTX, GANX, RNTX, VRCA, INKT, HYPD, AURX. Left out: APLM (period gap), OKYO (period gap), BSEM (no annual filing), HYFT (period gap). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (RNXT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more RNXT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to RNXTand get the insider, 13F, options, and confluence read in one view.